Combined Ranibizumab and Iluvien for Diabetic Macular Oedema
Status:
Withdrawn
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This trial investigated whether adding Iluvien sustained release steroid intravitreal eye
implant at the beginning of regular anti-VEGF (anti Vascular Endothelial Growth Factor)
intravitreal eye injection treatment for diabetic macular oedema would improve disease
stability and reduce the need for regular anti-VEGF intravitreal eye injections over first
two years. Diabetic macular oedema, accumulation of microscopic fluid at the back of the eye,
is a major cause of poor vision in patients with diabetes.
This is a double mask randomized control multisite trial, to be conducted at 10 NHS hospital
eye clinics in England.